INTRODUCTION
============

Intracerebral hemorrhage (ICH) represents only ∼10% to 15% of all stroke types.^[@R1]--[@R3]^ However, the outcome for patients with ICH is more severe, with a higher mortality and morbidity, and expends a greater amount of socioeconomic and health resources compared with ischemic stroke.^[@R1]--[@R3]^ Certain arteriolar pathological alterations have been noted in the cerebral arterioles of ICH patients (eg, death and the proliferation of arteriolar smooth muscle cells, ectasia and the subsequent formation of microaneurysms in arterioles,^[@R1]--[@R3]^ and microaneurysm rupture in arterioles).^[@R1],[@R4],[@R5]^ These arteriolar pathological variations in ICH could be triggered by certain conventional cardiovascular risk factors, including hyperlipidemia,^[@R3],[@R6]^ diabetes,^[@R1],[@R3],[@R4],[@R7],[@R8]^ hypertension,^[@R1]--[@R8]^ ischemic heart disease (IHD),^[@R2],[@R7],[@R8]^ and atrial fibrillation (AF).^[@R4],[@R7],[@R8]^ However, in ∼10% to 25% of patients with ICH, the risk factors for ICH remain unclear,^[@R9],[@R10]^ especially in younger patients.^[@R1],[@R9],[@R10]^

Numerous studies have presented powerful evidence that coronary microaneurysms could develop after the emergence of arterial ectasia in the coronary arteries, which could be triggered by chronic inflammatory processes.^[@R11]--[@R13]^ Moreover, previous investigations have linked ICH with various chronic cerebral arteriolar inflammations induced by autoimmune diseases (eg, rheumatoid arthritis \[RA\]^[@R14],[@R15]^ and systemic lupus erythematosus \[SLE\]^[@R14],[@R16]^) as well as viral infections (eg, varicella-zoster virus \[VZV\]^[@R17],[@R18]^ and human immunodeficiency virus \[HIV\]).^[@R17],[@R19]^ However, the precise mechanisms linking chronic inflammatory diseases with ectasia in cerebral arterioles and the subsequent generation and breaking of cerebral microaneurysms remain unclear.

Pelvic inflammatory disease (PID), a chronic inflammatory condition caused by an infection emerging from the cervix to the upper genital tract, is commonly diagnosed in young women.^[@R20]--[@R22]^ PID is characterized by frequent complications from the infections of *Chlamydia trachomatis* (*C trachomatis*) and *Neisseria gonorrhoeae (N gonorrhoeae)*.^[@R20]--[@R22]^ As reported in previous investigations, type 1 T helper cells (Th1), which are primarily responsible for cellular immunity and enhance the secretion of proinflammatory cytokines, and type 2 T helper cells (Th2), which are responsible for humoral immunity and modulate the functions of Th1, both play a critical role in the immune responses of PID induced by *C trachomatis* and *N gonorrhoeae*.^[@R23]--[@R25]^ Tseng et al^[@R26]^ found that a milder form of allergic rhinitis (AR), a Th2-modulated inflammatory disorder, could reduce the risk of ICH, and in an investigation with a short follow-up period (2004--2005),^[@R27]^ Chen et al found an increased risk of ischemic stroke among patients with PID. However, whether PID, a disease involving the immune response of both Th1 and Th2 cells, advances or attenuates the development of ICH remains unclear. With a large number of enrollees in the National Health Insurance (NHI) program of Taiwan, for our study, we used this claims database to measure the correlation between PID and ICH over a follow-up period of 13 years (1999--2011).

MATERIALS AND METHODS
=====================

Data Source
-----------

We used the Longitudinal Health Insurance Database (LHID), which consists of 1 million patient data from 1996 to 2000 that were extracted from the catalogue of beneficiaries in the National Health Insurance Research Database (NHIRD).^[@R26],[@R28]^ The NHIRD, which comprises \>98% of the population of Taiwan, was established on the basis of the NHI program implemented in 1995. The contents of the LHID include information on patients' medical registry facilities, their demographic data, and the types of medical care they underwent. The healthcare records of outpatients and inpatients in the LHID were required under the allowances of the insurance authority. To ensure patient privacy, the patient identification numbers used for linking data files were encrypted before the public release of the data. The disease diagnoses were determined in accordance with the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes.

Study Patients
--------------

We included participants of the NHI program who were newly diagnosed with PID (ICD-9-CM code 614) at the start of 1999 until the end of 2004, and with no history of stroke (ICD-9-CM codes 430-438), in the PID group according to the LHID, the data of which were drawn from the NHIRD. The first date of PID diagnosis was circumscribed as the entry date. The experimental group consisted of 25,508 women diagnosed with PID. By contrast, the control cohort comprised 4 times the number of patients in the PID group from the NHIRD, and they included women with neither PID nor a history of stroke (n = 102,032) who were frequency matched by age and entry year.

Outcome and Relevant Variables
------------------------------

The PID and control cases were followed until December 31, 2011, to evaluate those diagnosed with ICH (ICD-9-CM code 431). The variables relevant to ICH were age, and comorbidities, including hyperlipidemia (ICD-9-CM code 272), diabetes (ICD-9-CM code 250), hypertension (ICD-9-CM codes 401-405), IHD (ICD-9-CM codes 410-414), and AF (ICD-9-CM code 427.32). We also evaluated the ICH cases in association with these variables.

Statistical Analysis
--------------------

The spreads of the discrete and continuous variables between the PID and control cohorts were assessed by conducting the chi-square test and *t* test, respectively. The incidence rate of ICH per 1000 person-years was evaluated and computed from the date of entry until the first date of ICH occurrence, withdrawal from the insurance program, death, or December 31, 2011. The Cox regression model was used to determine the adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) in order to measure the risk of ICH development between the 2 groups. Further assessments of ICH risk were conducted by stratifying by age (\<35 years, 35--49 years, and ≥50years) and the common comorbidities of ICH.

For data assessment, the ICH risk was also evaluated in relation to PID severity, which was defined as patients receiving inpatient or outpatient medical services because of PID. We further categorized PID severity as patients with PID without hospitalization (mild group) and patients with hospitalization because of PID (severe group). The cumulative ICH risk for both PID and control groups was plotted through the analyses by using the Kaplan--Meier model, and the log-rank test was conducted to determine the differences between the 2 cohorts. Significance was circumscribed with a 2-tailed *P* value \< 0.05. All statistical calculations were executed using SAS (version 9.1, SAS Institute Inc., NC).

Ethics Statement
----------------

The NHIRD encrypts patient personal information to protect privacy and provides researchers with anonymous identification numbers associated with relevant claims information, including sex, date of birth, medical services received, and prescriptions. Therefore, patient consent is not required to access the NHIRD. This study was approved to fulfill the condition for exemption by the Institutional Review Board (IRB) of China Medical University (CMUH-104-REC2--115). The IRB also specifically waived the consent requirement.

RESULTS
=======

On the basis of the age distributions, no significant differences were found between the PID and control groups (Table [1](#T1){ref-type="table"}). More than 90% of the PID patients were \<50 years. Compared to control cohort, PID cohorts were with more comorbidities including hypertension (5.64% vs 5.08%), hyperlipidemia (4.76% vs 3.45%), diabetes (2.45% vs 1.89%), and IHD (2.84% vs 1.91%).

###### 

Demographic Data and Comorbidities of the Pelvic Inflammatory Disease and Control Groups
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The overall ICH incidence in the PID and comparison cohorts was 2.02 and 3.10 per 1000 person-years, respectively (Table [2](#T2){ref-type="table"}). After adjusting for age and the comorbidities of hyperlipidemia, diabetes, hypertension, IHD, and AF, we found that the aHR of ICH development was 0.67-fold (95% CI:0.50--0.90) for the PID group compared with those without PID. The ICH incidence rate in both groups increased with older age, and the age-specific risk for ICH in the PID group was lower than in the control cohort for all age groups, especially for older patients (Table [3](#T3){ref-type="table"}). The incidence rate of ICH increased in conjunction with comorbidities in both cohorts, even though the comorbidity-specific risk for ICH in the PID group was still lower than in the control cohort, either with or without comorbidities (Table [3](#T3){ref-type="table"}). All patients, with or without PID, but with the comorbidities of hypertension, diabetes, or IHD, were at a greater risk of ICH, especially those with hypertension (Table [2](#T2){ref-type="table"}).
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Incidence Rate and Hazard Ratio for Intracerebral Hemorrhage, Stratified by Demographic Factors and Comorbidities
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Incidence and Hazard Ratio for Intracerebral Hemorrhage Between the Pelvic Inflammatory Disease and Control Groups, Stratified by Demographic Factors and Comorbidities
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Our estimation results on the correlation between PID severity and ICH risk revealed a dose-response effect regarding the attenuation in ICH development; in other words, the risk of ICH decreased with a worsening PID severity (Table [4](#T4){ref-type="table"}). Compared with the control group, the aHR for patients with PID stratified by severity was 0.72 (95% CI:0.53--0.98) for the mild group and 0.30 (95% CI:0.10--0.92) for the severe group. The Kaplan--Meier graph displayed that the cumulative incidence of ICH was lower for the PID group than for the control cohort (log-rank *P* = 0.003) (Figure [1](#F1){ref-type="fig"}).
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Incidence and Hazard Ratio for Intracerebral Hemorrhage, Stratified by Whether Patients Diagnosed With Pelvic Inflammatory Disease Were Hospitalized During the Study Period
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![Cumulative intracerebral-hemorrhage-free rates between pelvic inflammatory disease (PID) and comparison cohorts, analyzed through the Kaplan--Meier model. PID = pelvic inflammatory disease.](medi-95-e2726-g005){#F1}

DISCUSSION
==========

Associations of extended ICH risk because of increased arterial ectasia in cerebral arterioles with inflammatory processes (eg, viral infections withVZV^[@R17],[@R18]^ and HIV^[@R17],[@R19]^) as well as dysimmunity disorders (eg, RA^[@R14],[@R15]^ and SLE^[@R14],[@R16]^) have been reported in previous investigations. In the present retrospective cohort research, we compared PID patients against those without this disease over a 13-year follow-up period (1999--2011). A 33% decrease in the ICH risk was found in the PID cohort (Table [2](#T2){ref-type="table"}). The ICH risk diminished for patients with either mild or severe PID, and we discerned a dose-response effect regarding the reduction of ICH risk on PID severity (Table [4](#T4){ref-type="table"}). As demonstrated in previous studies,^[@R29]--[@R31]^ Th2-associated immune responses have been shown to be correlated with anti-inflammatory properties, which might play a critical role in reducing ICH risk in patients with PID.

Age is the most crucial risk factor for ICH.^[@R1]--[@R9]^ However, among all the patients examined, regardless of whether they were diagnosed with PID, those at an advanced age had a higher age-specific ICH risk (Table [2](#T2){ref-type="table"}), and the incidence rate of ICH rose gradually with age in both the PID and control groups under study (Table [3](#T3){ref-type="table"}). Moreover, the aHR of ICH was lower in patients with PID compared with the control group, regardless of age stratification (Table [3](#T3){ref-type="table"}), and ICH risk decreased steadily in conjunction with the severity of PID (Table [4](#T4){ref-type="table"}). These findings further support the association between PID and the attenuation of ICH development.

Comorbidities for Intracerebral Hemorrhage
------------------------------------------

In several investigations, the authors have combined the risk of ICH with the male gender,^[@R1]--[@R8]^ older age,^[@R1]--[@R9]^ and the comorbidities of hyperlipidemia,^[@R3],[@R6]^ diabetes,^[@R1],[@R3],[@R4],[@R7],[@R8]^ hypertension,^[@R1]--[@R8]^ IHD,^[@R2],[@R7],[@R8]^ and AF.^[@R4],[@R7],[@R8]^ In the present study, the ICH risk for patients with PID increased in combination with the comorbidities of diabetes and hypertension (Table [3](#T3){ref-type="table"}).

STRENGTHS AND LIMITATIONS
=========================

With the advantages of using a large sample as well as the availability of a low loss-to-follow-up rate in a longitudinal arrangement, we could provide analyses with further stratification of variables, including age, prevalent comorbidities for ICH, and the severity of PID. The dose--response effect on reducing ICH risk associated with PID severity further strengthened the validity of our findings. Comorbidities could lead to variations in the link between PID and ICH development. In order to prevent healthcare fraud, the insurance claims for reimbursements for inpatient and outpatient services are surveyed strictly in the NHI program of Taiwan. The monitoring system for the NHI program lends further validity to the diagnoses reported in insurance claims.

However, our study was still subject to several limitations. First, other potential risk factors for cardiovascular diseases (eg, possible immunity variations resulting from PID and physical inactivity, which might affect patients by reducing the risk of ICH development) could not be obtained from the NHI database. Second, the immunity-correlated laboratory data, including the serum counts of Th1 and Th2, serum immunoglobulin levels, C-reactive protein serum levels, and the erythrocyte sedimentation rate were unavailable in the NHIRD. Hence, we could not assess the association between the different immune conditions in individual PID patients and ICH risk. Third, data on patients' private behavior (eg, cigarette smoking and alcohol consumption habits) were unavailable. Nevertheless, the low smoking rate among women in Taiwan (\<3.5%)^[@R32]^ implies that cigarette smoking did not appear to be a major confounder in the link between PID and ICH. Fourth, although we noted a higher prevalence of comorbidities for ICH in patients with PID compared with the control group, the results revealed that even with these risk factors, which could further advance the development of ICH, PID was still found to have a lower ICH risk. In numerous studies,^[@R29]--[@R31],[@R33],[@R34]^ Th2, which plays a crucial role in the generation of immunity in PID,^[@R20]--[@R22]^ has been found to be closely related to the control of anti-inflammatory responses. However, the precise mechanisms by which Th2-related anti-inflammatory effects protect PID patients from ICH development remain unclear. Future investigations on this issue are warranted to further confirm the correlation between PID and ICH development.

CONCLUSIONS
===========

The findings of this study revealed that the overall risk of ICH was lower in patients with PID; however, ICH risk may increase relative to a younger age as well as with certain common comorbidities of ICH. Further investigations are required to verify the findings of our study. These findings can serve as a reference for ICH prevention in PID patients, especially for those of a younger age.

Abbreviations: CIs = confidence intervals, HRs = hazard ratios, ICD-9-CM = International Classification of Diseases Ninth Revision Clinical Modification, ICH = intracerebral hemorrhage, NHIRD = National Health Insurance Research Database, PID = pelvic inflammatory disease.
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